SK Biopharmaceuticals, fresh off an FDA nod, preps for $850M IPO in January: report

Recent biopharma IPOs in South Korea include Samsung Biologics in 2016 and Celltrion in 2017. (Pixabay)

Right on the heels of an FDA approval for seizure med Xcopri, South Korea’s SK Biopharmaceuticals is reportedly planning an initial public offering to raise about $850 million.

The company plans to list shares in January and has chosen Citigroup and NH Investment & Securities as advisers for the process, the Financial Times reports, citing people familiar with the planning. 

News of the IPO comes after last week’s FDA approval for Xcopri from SK Biopharmaceuticals’ U.S. subsidiary, SK Life Science, to treat partial-onset seizures in adults. SK plans to launch the med itself next year, executives told FiercePharma. First, the DEA will have to schedule the drug. 

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

In anticipation of the rollout, SK has established an in-house commercial organization, including a marketing team, market access experts and a sales force. SK plans to launch with 100 to 125 sales reps, execs said. 

RELATED: SK Life Science plots 2020 launch for now-approved seizure drug Xcopri 

Over the span of more than a decade, SK Life Sciences independently discovered and developed the med. The company has licensed European rights to the drug to Arvelle Therapeutics, a spinoff from Axovant that secured $100 million in initial financing back in February. 

The drugmaker also has pipeline candidates in Lennox-Gastaut syndrome, ADHD, schizophrenia and more.

Other recent biopharma IPOs in South Korea include Samsung Biologics' $1.9 billion raise in 2016 and Celltrion's $858 million offering in 2017, according to the FT. 

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.